Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
660 participants
OBSERVATIONAL
2022-12-06
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Safety of New Oral Antivirals for COVID-19
NCT05894603
A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection
NCT05697055
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
NCT04613271
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
NCT04847622
A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
NCT05506176
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, we will observe the clinical outcomes (COVID-19 symptoms, hospitalization admission, mortality, long term COVID-19 symptoms) of COVID-19 study participants seen in the health clinic up to 90 days from their initial visit to the health clinic . The hypothesis is that oral antiviral is beneficial in preventing disease progression and reducing long term COVID-19 symptoms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral Antiviral Group
Study participant initiated with oral antiviral (nirmatrelvir plus ritonavir or molnupiravir) for the treatment of COVID-19
Oral Antiviral
Nirmatrelvir plus ritonavir or molnupiravir
Non Oral Antiviral Group
Study participant not initiated with oral antiviral for the treatment of COVID-19
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral Antiviral
Nirmatrelvir plus ritonavir or molnupiravir
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinical Research Centre, Malaysia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ee Vien Low, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Clinical Research Center, Malaysia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinik Kesihatan Kajang
Kajang, Selangor, Malaysia
Klinik Kesihatan Banadar Botanik
Klang, Selangor, Malaysia
Klinik Kesihatan Bukit Kuda
Klang, Selangor, Malaysia
Klinik Kesihatan Pandamaran
Klang, Selangor, Malaysia
Klinik Kesihatan Seksyen 19
Petaling Jaya, Selangor, Malaysia
Klinik Kesihatan Seksyen 7
Petaling Jaya, Selangor, Malaysia
Klinik Kesihatan Puchong Batu 14
Subang Jaya, Selangor, Malaysia
Klinik Kesihatan Taman Medan
Petaling Jaya, , Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lih Bing Lau
Role: primary
Mohan Dass Pathmanathan
Role: backup
Salbiah Mohamed Isa
Role: primary
Cheng Lee Ooi
Role: backup
Siti Fairuz
Role: primary
Ee Vien Low
Role: backup
Zienna Zufida Zainol Rashid
Role: primary
Cheng Lee Ooi
Role: backup
Mohammad Ariff Fahmi Ahmad Zawawi
Role: primary
Cheng Lee Ooi
Role: backup
Azah Abdul Samad
Role: primary
Cheng Lee Ooi
Role: backup
Izwan Effendy Ismail
Role: primary
Ee Vien Low
Role: backup
Suet Yin Chow
Role: primary
Ee Vien Low
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NMRR ID-22-00938-2YN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.